Patient Treated for Alcoholism With CITA Biomedical's Proprietary Treatment Program to End Alcohol Dependence Remains Craving Free, No Withdrawal Symptoms, No Cravings for Alcohol
BEVERLY HILLS, Calif., Aug 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today announced that the first U.S. Detoxification and NeuroAdaptation (DNA) for Alcohol patient continues to be craving free one month after treatment. DNA for Alcohol is a part of a family of treatments called DNA for Addictions. The DNA for Addictions treatment family also includes DNA for Cocaine, DNA for Alcohol and Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
The patient said he is the happiest he has been in his life. He has even been able to enter a bar and have no desire for an alcoholic drink. Treated with DNA for Alcohol at the beginning of July the patient, a 62-year-old male who had been dependant on alcohol for over 40 years was consuming an average of 1.5 liters of gin, brandy, and beer a day. He is now saving the money he once spent on alcohol. The treatment was administered to the patient over two consecutive days where the patient experienced no symptoms of withdrawal.
DNA for Alcohol establishes an accelerated alcohol treatment in the fight against alcoholism, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Alcoholism causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. The disorder of alcoholism has historically been treated only through behavioral intervention, this is in contrast to CITA's DNA for Alcohol treatment which provides a solution for treating both the physiological and psychological components of this devastating condition.
Patients treated in Europe last year experienced a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating alcoholism. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.
"Treating both the physical and psychological components of alcoholism are key to DNA for Alcohol's success and what sets DNA apart from other treatments," said Joseph Dunn, president and CEO of CITA Biomedical. "We anticipate that the benefits this patient is experiencing will also be realized by the thousands of patients we plan to treat for alcohol dependence in the coming year. CITA's mission is to make the transition from substance dependence to independence as quick, smooth and humane as possible, with DNA for Addictions we've done that."
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently began a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions: CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com or www.cita1.com .
UROD is a registered trademark of CITA Biomedical, Inc.
For further information, please contact Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971, jryon@citabio.com.
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971, jryon@citabio.com
. |
